NeoTYPE® Endometrial Tumor Profile

<p>The NeoTYPE Endometrial Tumor Profile analyzes 47 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If global HER2 (Other) IHC w/Breast Scoring result is 2+, case will reflex to global HER2 (Other) FISH w/Breast Scoring unless reflex to tech-only FISH or reflex opt-out is requested. If Pan-TRK IHC is expressed or equivocal, reflex to either NTRK NGS Fusion Panel (Default) or NTRK 1-3 FISH Panel will be added. A microsatellite instability (MSI) NGS result of "indeterminate" will create a reflex to MSI by PCR as long as the tumor percentage is &ge;40% and paired normal tissue is available. NGS (40 genes + 2 biomarkers): AKT1, APC, ARID1A, ATM, ATR, ATRX, BRAF, BRCA1, BRCA2, CDH1, EGFR, EPCAM, ESR1, FBXW7, FGFR1, FGFR2, FGFR3, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), MLH1, MSH2, MSH6, MTOR, MUTYH, NRAS, PDGFRA, PIK3CA, PIK3R1, PMS2, POLE, PTEN, PTPN11, SMAD4, SMARCA4, SMO, SRC, TERT Promoter, TP53, Tumor Mutation Burden (TMB) FISH (2 FISH): MET, PTEN (tech-only available) IHC (3 biomarkers): HER2 (Other) IHC w/Breast Scoring, PD-L1 LDT, Pan-TRK (tech-only available for HER2 and PD-L1).</p>